<?xml version="1.0" encoding="UTF-8"?>
<fig id="pone.0229239.g002" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pone.0229239.g002</object-id>
 <label>Fig 2</label>
 <caption>
  <title>SVR12 rates after treatment with G/P according to mITT.</title>
  <p>Abbreviations: SVR, sustained virologic response; G/P, glecaprevir/pibrentasvir; mITT, modified intention-to-treat; SS, standard setting; DOT, directly observed therapy; LTFU, lost to follow-up; HCV, hepatitis C virus; GT, genotype. A—All patients (n = 141/145). 
   <sup>a</sup> including one patient who died 16 weeks after end of therapy for reasons not related to treatment after showing a negative HCV-RNA PCR result three weeks after end of therapy. B—Patients with advanced fibrosis (n = 21/21). Advanced fibrosis was defined as F3-F4: ≥9.5 kPa according to transient elastography. C—Patients with HCV GT3 infection (n = 54/56).
  </p>
 </caption>
 <graphic xlink:href="pone.0229239.g002" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
